Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» uniQure
uniQure
After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus
After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus
Fierce Pharma
uniQure
Hemgenix
gene therapy
hemophilia A
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Big pharma’s new year catalysts
Big pharma’s new year catalysts
EP Vantage
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Flag link:
Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal
Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal
Fierce Biotech
Bristol Myers Squibb
uniQure
gene therapy
Flag link:
uniQure, CSL claim first okay for hemophilia B gene therapy
uniQure, CSL claim first okay for hemophilia B gene therapy
Pharmaphorum
uniQure
CSL
hemophila B
gene therapy
Hemgenix
FDA
Flag link:
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
Fierce Biotech
uniQure
clinical trials
Huntington's disease
AMT-130
Flag link:
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review
CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review
BioSpace
CSL Behring
uniQure
hemophilia B
gene therapy
FDA
priority review
etranacogene dezaparvovec
Flag link:
As biotech retreats, gene therapy companies retrench and redraw plans
As biotech retreats, gene therapy companies retrench and redraw plans
BioPharma Dive
biotech
gene therapy
layoffs
R&D
Bluebird Bio
Allogene
uniQure
Flag link:
Fresh data show UniQure's hemophilia gene therapy appears to hold up
Fresh data show UniQure's hemophilia gene therapy appears to hold up
BioPharma Dive
uniQure
gene therapy
hemophilia
hemophilia B
Flag link:
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals
Flag link:
Gene therapy for Fabry: early stages, promising results
Gene therapy for Fabry: early stages, promising results
BioPharma Dive
gene therapy
Fabry disease
uniQure
Avrbio
Freeline Therapeutics
Sangamo Therapeutics
Flag link:
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Motley Fool
clinical trials
Novartis
Biogen
SAGE Therapeutics
uniQure
Pfizer
Roche
Flag link:
Biopharma takeovers dry up
Biopharma takeovers dry up
EP Vantage
M&A
MorphoSys
Constellation Pharmaceuticals
Sanofi
Tidal Therapeutics
uniQure
Corlieve Therapeutics
Strongbridge Biopharma
Xerix Pharmaceuticals
Novellus Therapeutics
Brooklyn Immunotherapeutics
Flag link:
With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
Endpoints
uniQure
M&A
Corlieve Therapeutics
AMT-260
gene therapy
temporal lobe epilepsy
Flag link:
8 key clinical trials to watch for the rest of 2021
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
UniQure moves Huntington's gene therapy to next phase of key trial
UniQure moves Huntington's gene therapy to next phase of key trial
BioPharma Dive
uniQure
Huntington's disease
clinical trials
gene therapy
AMT-130
Flag link:
FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump
FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump
Fierce Biotech
uniQure
hemophilia
gene therapy
FDA
Flag link:
Pages
1
2
3
next ›
last »